Vanda Pharmaceuticals Says Experimental Anxiety Treatment Misses Primary Endpoint
Vanda Pharmaceuticals announced its Phase 3 trial for VQW-765 failed to meet primary endpoints for treating acute social anxiety disorder.
Stocks · News reference
Vanda Pharmaceuticals' Phase III Clinical Study Of VQW-765 In Adults With Social Anxiety Disorder Did Not Meet Its Primary Endpoint; VQW-765 Was Safe And Well-Tolerated
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
HC Wainwright & Co. Reiterates Buy on Vanda Pharmaceuticals, Maintains $20 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Vanda Pharmaceuticals (NASDAQ:VNDA) with a Buy and maintains $20 price target.
Vanda Eyes First FDA-Approved Delayed Sleep-Wake Disorder Drug
Vanda's Phase 3 trial of HETLIOZ for DSWPD met its primary endpoint, advancing sleep onset by 42.5 minutes. sNDA submission planned.